Synklino raises seed round to develop breakthrough infection treatment for transplant patients
Synklino ApS, an emerging biotech company developing first-in-class breakthrough treatment to eliminate cytomegalovirus (CMV) infections in the transplant setting, today announces the successful closing of a seed financing led by Eir Ventures and Vaekstfonden.
Synklino has set its sight on billion-dollar transplant market
Synklino has set its sight on billion-dollar transplant market
BioInnovation Institute invests DKK10m in Synklino
We are proud to announce that the Novo Nordisk Foundation BioInnovation Institute (BII) has decided to invest DKK 10m ($1.5m) in Synklino. As a part of BII’s Creation House Programme we will have an ideal opportunity to accelerate our technical and commercial validation, to strengthen the company’s core competences, and attract additional funding that can bring our drug candidate further in pre-clinical development
Synklino has employed John Haurum as chairman of the board
John Haurum is to help Synklino develop a treatment against cytomegalovirus (CMV) infection in patients undergoing transplantation. The virus infection is quite common and often relatively harmless, but it can be more severe for transplantation patients receiving treatment with immunosuppressant drugs.
Synklino is founded
Synklino is founded by Professor in Pharmacology at the University of Copenhagen, Mette M. Rosenkilde, Ph.d. in Protein Crystallography, Mads G. Jeppesen, and life science entrepreneur Thomas N. Kledal, PhD and MBA, who is the company CEO and former head of Virology DTU, Veterinary Institute, Technical University of Denmark.